Triumeq is a fixed-dose tablet containing 50mg of dolutegravir, 600mg of abacavir and 300mg of lamivudine. Triumeq is manufactured by ViiV Healthcare.

Dolutegravir is an HIV integrase inhibitor also marketed alone as Tivicay. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors also marketed as the fixed-dose combination Kivexa or singly as Ziagen and Epivir. These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

Triumeq is approved for use in adults and adolescents over the age of 12. Triumeq received marketing authorisation in the European Union in September 2014 and US marketing approval in August 2014. A dispersible formulation for children weighing between 14kg and 25kg received marketing approval in the European Union in December 2022.

Triumeq is dosed as one purple tablet once daily, with or without food.

Triumeq contains abacavir, which is associated with a risk of life-threatening hypersensitivity reaction in a small minority of people with a specific genetic profile. Everyone should undergo a genetic test to rule out potential abacavir hypersensitivity before starting this combination. See abacavir for further information on the symptoms of abacavir hypersensitivity and screening for hypersensitivity.

For more information on Triumeq’s component drugs, including further details of potential side-effects, efficacy and drug resistance, see dolutegravir, abacavir and lamivudine.